One To Watch

Evaxion Biotech

Company Overview

A Danish clinical-stage TechBio company using its proprietary AI-Immunology platform to design personalized cancer vaccines and infectious disease candidates, with its bacterial vaccine EVX-B3 already out-licensed to MSD in a deal worth up to $592 million. Evaxion A/S (NASDAQ: EVAX) positions itself at the intersection of artificial intelligence and immunology, training computational models to decode immune system responses and select antigens with precision that conventional methods cannot match. The EVX-B3 out-licensing to MSD marked the first time a major pharma company licensed an AI-designed vaccine candidate — a commercial validation that the company carries prominently into its next phase of growth.

Headquarters and Global Presence

Evaxion is headquartered in Copenhagen, Denmark, and trades on the NASDAQ exchange under the ticker EVAX. Its operational footprint is primarily Nordic, though clinical activity and the MSD partnership give it commercial reach into the US market.

Founding and History

Evaxion was founded to apply machine learning to vaccine antigen discovery, a field where traditional empirical approaches have historically produced low success rates. The company listed on NASDAQ, bringing it into the US capital markets and raising its profile among transatlantic investors. The out-licensing of EVX-B3 to MSD and its Q3 2025 revenue contribution of $7.5 million represent the most significant commercial milestone to date. In November 2025, the board recruited Dr Helen Tayton-Martin as CEO, signaling a strategic push toward partnerships and pipeline acceleration.

Therapy Areas and Focus

Evaxion's pipeline spans three disease domains: cancer, infectious disease, and — most recently — autoimmune conditions, into which the AI-Immunology platform is being extended with training planned for H2 2026. On the cancer side, the focus is personalized neoantigen vaccines, where each patient's tumor mutational profile informs a bespoke immunogen. On infectious disease, bacterial pathogens are the current priority, with EVX-B3 addressing an undisclosed bacterial indication under MSD's stewardship. The autoimmune expansion is early-stage but signals an intent to extract maximum platform value across immune-mediated disease categories.

Technology Platforms and Modalities

The AI-Immunology platform comprises multiple proprietary AI models trained to predict which antigens will elicit functional T-cell and antibody responses in humans — a problem that has defeated rational design approaches for decades. The platform underpins all pipeline programs, processing genomic and proteomic inputs to select immunogenic targets with higher throughput and precision than wet-lab screening alone. For cancer vaccines, this means rapidly identifying patient-specific neoantigens from tumor sequencing data; for bacterial vaccines, it means selecting conserved surface antigens across strain diversity. The commercial proof point — MSD licensing EVX-B3 — gives the platform credibility that most AI-biology companies at this stage have yet to earn.

Key Pipeline and Programs

EVX-01 is Evaxion's lead personalized cancer vaccine, currently in Phase II trials in advanced melanoma. The most recent readout — two-year data — showed a 75% objective response rate across 12 of 16 evaluable patients, a signal that is clinically notable even at this cohort size. Three-year efficacy data are expected in H2 2026, alongside additional biomarker analyses that will help characterize which patients derive the greatest benefit. The vaccine is designed using patient-specific neoantigen profiling generated by the AI-Immunology platform.

EVX-B3 is a bacterial vaccine candidate out-licensed to MSD, marking the first AI-designed vaccine licensed by a major pharmaceutical company. Evaxion received $7.5 million in out-licensing revenue from MSD in Q3 2025, with total potential milestones of up to $592 million. An MSD option exercise expected later in 2026 could bring an additional $10 million near-term.

EVX-04 is the next infectious disease candidate moving toward the clinic; a Phase I regulatory filing is targeted for H2 2026. EVX-B4, a further bacterial vaccine candidate, is at antigen design and preclinical validation stage, with that work also slated for H2 2026.

Recent Developments

Dr Helen Tayton-Martin joined as CEO on November 24, 2025, bringing 17 years of experience at Adaptimmune — where she co-founded the company and rose to Chief Business and Strategy Officer — alongside a PhD in molecular immunology and an MBA from London Business School. In April 2026, Evaxion shareholders approved expanded financing authorities, including warrant issuance up to DKK 11.9 million and convertible loan notes up to DKK 73.5 million, extending strategic flexibility with a cash runway running into H2 2027. The platform expansion into autoimmune diseases was announced alongside the Q3 2025 update, broadening the addressable opportunity beyond oncology and infectious disease.

Key Personnel

Helen Tayton-Martin serves as Chief Executive Officer. She co-founded Adaptimmune, served as its COO and later Chief Business and Strategy Officer over 17 years, and holds a PhD in molecular immunology and an MBA from London Business School. Birgitte Roenoe serves as Chief Scientific Officer and Chief Operating Officer, combining scientific leadership with operational oversight across the platform and pipeline. Andreas Mattsson serves as Chief AI Officer, responsible for the development and deployment of the AI-Immunology models that underpin every program.

Strategic Partnerships

The MSD (Merck) out-licensing agreement for EVX-B3 is Evaxion's defining commercial relationship, generating $7.5 million in Q3 2025 and carrying up to $592 million in future milestone payments. A further MSD option exercise in 2026 could add $10 million. The deal represents the first time a major pharma company has licensed an AI-designed vaccine candidate, lending external validation to the platform's commercial relevance.

FAQ Section

The EVX-B3 out-licensing to MSD is the first instance of a major pharmaceutical company licensing an AI-designed vaccine candidate — a milestone that validates Evaxion's platform in a way that internal clinical data alone cannot. The deal structure, with up to $592 million in milestones and a potential option exercise bringing $10 million in 2026, also provides Evaxion with non-dilutive revenue that extends its cash runway into H2 2027. For a small TechBio, that combination of proof-of-concept credibility and balance-sheet insulation is strategically significant.

Conventional vaccine development relies heavily on empirical screening of candidate antigens, a slow and attrition-heavy process — particularly for highly variable pathogens or heterogeneous tumor profiles. Evaxion's AI-Immunology platform uses proprietary machine learning models trained on immunological data to predict which antigens will generate functional T-cell or antibody responses in humans before any wet-lab work begins. For personalized cancer vaccines, this means processing each patient's tumor mutational landscape to select neoantigens; for bacterial vaccines, it means identifying conserved surface targets across strain diversity. The platform's ability to accelerate and de-risk this selection step is the company's core commercial proposition.

The neoantigen vaccine space has attracted significant capital — Moderna and BioNTech both have programs — but most approaches are computationally intensive without a dedicated AI platform built specifically around immune system modeling. Evaxion's differentiation is the depth of the AI-Immunology stack, which spans cancer, bacterial, and now autoimmune applications from a single underlying infrastructure. The MSD validation of the bacterial program suggests the platform produces output that a major pharma scientific team found credible enough to license rather than replicate. That external endorsement is harder for competitors to point to.

Two-year follow-up data in advanced melanoma showed a 75% objective response rate across 16 evaluable patients — 12 responding — which is a striking number in a heavily pretreated setting. The cohort is small and uncontrolled, which means the data warrant cautious interpretation; the absence of a randomized comparator makes it difficult to isolate the vaccine's contribution from prior or concurrent checkpoint inhibitor use. The commercially important readout will be the three-year efficacy data expected in H2 2026, where durability of response will either strengthen or complicate the development case.

Evaxion currently has eight candidates across cancer and infectious disease — three oncology programs and five infectious disease — with a ninth track being opened in autoimmune via platform extension planned for H2 2026. The autoimmune move follows a logic familiar in AI-platform companies: once the underlying models are trained to predict immune activation, redirecting them toward immune suppression or tolerance induction is a natural extension. Whether execution bandwidth in a small clinical-stage company can support three disease domains simultaneously is the operational question the new CEO will need to answer.

Evaxion is at the early-to-mid clinical stage: EVX-01 is in Phase II, EVX-B3 has been out-licensed, EVX-04 is approaching a Phase I regulatory filing (targeted H2 2026), and EVX-B4 is in preclinical antigen validation. The company has runway into H2 2027 and a financing structure — following the April 2026 shareholder approvals — that provides access to convertible capital if needed. The H2 2026 cluster of milestones makes the second half of this year the most data-rich period in the company's history.

The near-term picture is busy, with several binary events converging in H2 2026. Key watchpoints include:

Want to Update your Company's Profile?